Category: Pharmaceuticals

Pharmaceuticals

How to Afford CPAP + GLP-1 Polytherapy

What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?

Pharmaceuticals

Idorsia Reports Q1 2026 Results, Highlighting Pediatric Daridorexant Data and Expanding Clinical Evidence

The company’s first-quarter update emphasizes strong phase 2 results for daridorexant in children, ongoing real-world studies in patients with co-morbidities, and advancements in its sleep medicine pipeline.

Pharmaceuticals

Lilly to Acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders

The acquisition centers on Centessa’s pipeline of orexin receptor 2 agonists, including lead candidate cleminorexton, targeted for narcolepsy and idiopathic hypersomnia.

Prescription Drugs

Idorsia Reports Strong 2025 Financials with QUVIVIQ Sales More Than Doubling

The Swiss biotech company expects a pediatric insomnia study readout in 2026.

Over-the-Counter Treatments

Study: Over 1 in 5 Young Adults Use Cannabis or Alcohol for Sleep Aid

Findings reveal a high reliance on cannabis for sleep onset among adults aged 19 to 30, prompting calls for better clinical screening regarding substance use.

Emerging Compounds

Japan Grants Orphan Drug Designation to Eisai’s Novel Orexin Agonist for Narcolepsy

E2086, a selective orexin 2 receptor agonist, aims to address the pathophysiology of narcolepsy by activating orexinergic neurons.